33.23

2.13% 0.805

Stoke Therapeutics Inc (STOK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Stoke Therapeutics Inc stock is traded at $33.23, with a volume of 222.13K. It is up +2.13% in the last 24 hours and up +10.36% over the past month. Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Previous Close:

$32.43

Open:

$32.82

24h Volume:

222.13K

Relative Volume:

0.33

Market Cap:

$2.07B

Revenue:

$32.08M

Net Income/Loss:

$-169.77M

P/E Ratio:

-11.70

EPS:

-2.8418

Net Cash Flow:

$-147.70M

1W Performance:

+1.22%

1M Performance:

+10.36%

6M Performance:

-5.83%

1Y Performance:

+183.32%

1-Day Range:

$32.11

$33.25

1-Week Range:

$31.26

$33.50

52-Week Range:

$11.66

$40.22

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name

Stoke Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

781-430-8200

Address

45 WIGGINS AVENUE, BEDFORD, MA

Employee

170

Twitter

@stoketx

Next Earnings Date

2026-08-11

Latest SEC Filings

STOK's Discussions on Twitter

Compare STOK vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STOK Stoke Therapeutics Inc	33.23	2.04B	32.08M	-169.77M	-147.70M	-2.8418
VRTX Vertex Pharmaceuticals Inc	523.93	134.02B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	670.63	68.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	925.67	58.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	316.84	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	191.05	40.23B	742.00K	-1.37B	-1.07B	-7.0731

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Feb-05-26	Initiated	Guggenheim	Buy
Jan-05-26	Resumed	Chardan Capital Markets	Buy
Jul-18-25	Initiated	Jefferies	Buy
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral
Apr-26-23	Resumed	Canaccord Genuity	Buy
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-31-22	Initiated	Jefferies	Buy
Dec-03-21	Initiated	BofA Securities	Buy
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight
May-18-21	Initiated	UBS	Neutral
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy
Dec-11-20	Reiterated	Needham	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-29-20	Resumed	JP Morgan	Neutral
Sep-29-20	Initiated	Needham	Buy
Dec-18-19	Initiated	Wedbush	Outperform
Nov-12-19	Initiated	BTIG Research	Buy
Oct-25-19	Initiated	H.C. Wainwright	Buy
Jul-15-19	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Cowen	Outperform
Jul-15-19	Initiated	Credit Suisse	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight

View All

Stoke Therapeutics Inc Stock (STOK) Latest News

10:59 AM

Stoke Therapeutics holds the focus. Investors await the next evidence - AD HOC NEWS

10:59 AM

10:43 AM

Moran Wealth Management LLC Takes $1.32 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat

10:43 AM

Jul 06, 2026

Stoke Therapeutics (STOK) CMO sells 7,228 shares in planned 10b5-1 trades - Stock Titan

Jul 06, 2026

Jul 05, 2026

Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT) - TradingView

Jul 05, 2026

Jul 01, 2026

STOK (NASDAQ) lists 7,228 RSUs and reports two 10b5-1 sales - Stock Titan

Jul 01, 2026

Stoke Therapeutics (STOK) Edges Lower as Stock Consolidates Near Key LevelsETF Flow - dars.gov.et

Jul 01, 2026

Jun 30, 2026

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome - BioSpace

Jun 30, 2026

Stoke Therapeutics Advances Zorevunersen in Dravet Syndrome Stud - GuruFocus

Jun 30, 2026

Stoke Therapeutics (STOK) Advances Phase 3 Study and NDA Plans - GuruFocus

Jun 30, 2026

Stoke Therapeutics Completes Enrollment in Phase 3 Dravet Trial - TipRanks

Jun 30, 2026

Stoke completes phase 3 enrollment for Dravet syndrome drug By Investing.com - Investing.com Canada

Jun 30, 2026

Stoke CEO Ian Smith to speak April 14 at Needham healthcare event - Stock Titan

Jun 30, 2026

Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR; Q3 2027 readout, rolling NDA in 2027 - TradingView

Jun 30, 2026

Stoke Therapeutics (NASDAQ: STOK) completes Phase 3 Dravet trial enrollment, targets 2027 NDA - Stock Titan

Jun 30, 2026

Jun 29, 2026

Dravet Syndrome Foundation (DSF) Announces 2026 Community Award Winners - EIN Presswire

Jun 29, 2026

Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell 3000E Index - marketscreener.com

Jun 29, 2026

Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics (STOK)? - simplywall.st

Jun 28, 2026

Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Assenagon Asset Management S.A. Sells 320,708 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat

Jun 27, 2026